Literature DB >> 21624047

Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort.

J B Olesen1, G Y H Lip, P R Hansen, J Lindhardsen, O Ahlehoff, C Andersson, P Weeke, M L Hansen, G H Gislason, C Torp-Pedersen.   

Abstract

BACKGROUND: Oral anticoagulation (OAC) in patients with atrial fibrillation (AF) is a double-edged sword, because it decreases the risk of stroke at the cost of an increased risk of bleeding. We compared the performance of a new bleeding prediction scheme, HAS-BLED, with an older bleeding prediction scheme, HEMORR(2)HAGES, in a cohort of 'real-world' AF patients.
METHODS: By individual-level-linkage of nationwide registers, we identified all patients (n = 118,584) discharged with non-valvular AF in Denmark during the period 1997-2006, with and without OAC. Major bleeding rates during 1 year of follow-up were determined, and the predictive capabilities of the two schemes were compared by c-statistics. The risk of bleeding associated with individual risk factors composing HAS-BLED was estimated using Cox proportional-hazard analyses.
RESULTS: Of AF patients receiving OAC (n = 44,771), 34.8% and 47.3% were categorized as 'low bleeding risk' by HAS-BLED and HEMORR(2)HAGES, respectively, and the bleeding rates per 100 person-years were 2.66 (95% confidence interval [CI], 2.40-2.94) and 3.06 (2.83-3.32), respectively. C-statistics for the two schemes were 0.795 (0.759-0.829) and 0.771 (0.733-0.806), respectively. The risk factors composing HAS-BLED were associated with varying risks, with a history of bleeding (hazard ratio [HR] 2.98; 95% CI 2.68-3.31) and being elderly (HR 1.93; 95% CI 1.71-2.18) being associated with the highest risks. Comparable results were found in AF patients not receiving OAC (n = 77,813).
CONCLUSIONS: In an unselected nationwide cohort of hospitalized patients with atrial fibrillation, the HAS-BLED score performs similarly to HEMORR(2)HAGES in predicting bleeding risk but HAS-BLED is much simpler and easier to use in everyday clinical practise.
© 2011 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21624047     DOI: 10.1111/j.1538-7836.2011.04378.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  41 in total

1.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Underuse of Oral Anticoagulants and Inappropriate Prescription of Antiplatelet Therapy in Older Inpatients with Atrial Fibrillation.

Authors:  Lorette Averlant; Grégoire Ficheur; Laurie Ferret; Stéphane Boulé; François Puisieux; Michel Luyckx; Julien Soula; Alexandre Georges; Régis Beuscart; Emmanuel Chazard; Jean-Baptiste Beuscart
Journal:  Drugs Aging       Date:  2017-09       Impact factor: 3.923

3.  Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism.

Authors:  Waltraud Leiss; Marie Méan; Andreas Limacher; Marc Righini; Kurt Jaeger; Hans-Jürg Beer; Joseph Osterwalder; Beat Frauchiger; Christian M Matter; Nils Kucher; Anne Angelillo-Scherrer; Jacques Cornuz; Martin Banyai; Bernhard Lämmle; Marc Husmann; Michael Egloff; Markus Aschwanden; Nicolas Rodondi; Drahomir Aujesky
Journal:  J Gen Intern Med       Date:  2014-08-21       Impact factor: 5.128

4.  Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017.

Authors:  Junya Zhu; G Caleb Alexander; Saman Nazarian; Jodi B Segal; Albert W Wu
Journal:  Pharmacotherapy       Date:  2018-07-26       Impact factor: 4.705

5.  The changing characteristics of atrial fibrillation patients treated with warfarin.

Authors:  Andrew Putnam; Xiaokui Gu; Brian Haymart; Eva Kline-Rogers; Steve Almany; Jay Kozlowski; Gregory D Krol; Scott Kaatz; James B Froehlich; Geoffrey D Barnes
Journal:  J Thromb Thrombolysis       Date:  2015-11       Impact factor: 2.300

Review 6.  The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants.

Authors:  Jamshed Dalal; Abhay Bhave; Abraham Oomman; Amit Vora; Anil Saxena; Dhiman Kahali; Fali Poncha; D S Gambhir; Jaydip Ray Chaudhuri; Nakul Sinha; Saumitra Ray; S S Iyengar; Suvro Banerjee; Upendra Kaul
Journal:  Indian Heart J       Date:  2015-11-24

Review 7.  Assessing bleeding risk in patients taking anticoagulants.

Authors:  Marwa Shoeb; Margaret C Fang
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

Review 8.  Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis.

Authors:  Daniel Caldeira; João Costa; Ricardo M Fernandes; Fausto J Pinto; Joaquim J Ferreira
Journal:  J Interv Card Electrophysiol       Date:  2014-07-11       Impact factor: 1.900

Review 9.  Stroke And Bleeding Risk Assessment: Where Are We Now?

Authors:  Mikhail S Dzeshka; Gregory Y H Lip
Journal:  J Atr Fibrillation       Date:  2014-04-30

Review 10.  Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives.

Authors:  Francesco De Sensi; Tom De Potter; Alberto Cresti; Silva Severi; Günter Breithardt
Journal:  Cardiovasc Diagn Ther       Date:  2015-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.